Our mission is to be Your Easy Genetics Laboratory. Whether you are in Lisbon, Porto, Milan, Rio de Janeiro, Madrid, Cordoba, etc., we aim to provide patients, doctors, scientists, veterinary professionals, and students with an easy and secure channel. At STAB VIDA, we aspire to create an efficient flow for your samples, data, and information, supported by laboratories with highly qualified teams, always with the primary goal of delivering the results you need.

The last decades have witnessed the emergence of information and communication technologies; however, the 21st century will be characterized by advances in genetic technologies, paving the way for new products and markets. This sector represents a high-potential business and is of growing interest to governments, which have highlighted it as a strategic priority in the development of research in genomics and proteomics. It is in this challenging environment that STAB VIDA operates, constantly seeking to improve its performance and explore new opportunities.

In a broader context, our mission involves a continuous commitment to innovation and the adoption of new technologies in the field of biotechnology, through research and development, technology transfer, and a suitable commercial approach for products and services prepared for the global market.

CERTIFICATION AREAS

ISO 9001:2015

Performing genetic tests: PCR, nucleic acid sequencing by Sanger and Next Generation Sequencing (NGS).

ISO 13485:2018

Design and production of in vitro diagnostic medical devices: reagents and equipment based on fluorescence techniques.

QUALITY POLICY

The Management of STABVIDA, Lda., aware of the strategic relevance that stakeholders (customers, legal and regulatory entities, suppliers, partners, and company collaborators) have for the life of the company through the services and products it provides, has established its Quality Policy based on the following principles:

• Satisfaction of customer and user needs, corresponding to their expectations;
• Compliance with contractual, legal, and regulatory requirements applicable to its activities;
• Full compliance with agreements and contracts established with suppliers;
• Adherence to professional best practices in the provision of services and products;
• Compliance with ISO 9001:2015 and ISO 13485:2018 quality management standards;
• Continuous improvement of the quality of laboratory services provided and products marketed, as well as the effectiveness and efficiency of implemented quality management systems;
• Promotion of continuous training tailored to each employee, recognizing their performance and making the most of their abilities and skills, along with salary appreciation;
• Leadership ensuring an internal environment that fosters motivation and engagement among employees to fully achieve the company's objectives;
• Conducting business activities with a risk-oriented mindset, both at the strategic and operational levels.

Management encourages all employees to apply these principles within the scope of their responsibilities and duties.

Caparica, January 24th, 2024

STAB VIDA is strategically located in the research and technology park of Madan Parque - FCT / UNL, with administrative and financial facilities, fully equipped laboratories with ISO9001:2015 and ISO13485:2018 certifications and a team specialized with more than 20 years of experience in the areas of genetics and genomics using PCR and nucleic acid sequencing technologies.

STAB VIDA, created in 2001, is a Portuguese SME in the field of biotechnology made up of 30 employees and an exclusive line of genetics and genomics products and services. Currently, its commercial territory covers Portugal, Spain, the United Kingdom, Italy, South America (Brazil, Chile and Uruguay) and Africa (Angola and Nigeria). The STAB VIDA team is made up of a CEO, CFO, COO, Project Manager, laboratory and manufacturing technicians, researchers and a commercial team.

STAB VIDA also has extensive experience in participating and coordinating national and European projects (FP6, FP7 and H2020). Special mention should be made of the participation of STAB VIDA in the EuroGentest NoE FP6 project as it allowed the entire genetic testing process to be harmonized, from sampling to processing, across Europe, which will be extremely important for the implementation of the easierNGS project and coordination of the Pulmagene, LungCard FP7 and LungCARD RISE projects, specifically in the design of the lung cancer pharmacogenomics NGS panel.